Hira Khalid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hira Khalid has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Emmanuel Edigberhi
Department of Molecular Biology and Genetics, University of Benin, Benin City, Nigeria
3 shared publicationsArienmughare Oghenetega
Department of Medicine, University of Benin, Benin City, Nigeria
2 shared publicationsNimrah Bhatti
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
2 shared publicationsOsamagbe Osaghae
Department of Molecular Biology and Genetics, University of Benin, Benin City, Nigeria
2 shared publicationsRifqa Amjad
King Edward Medical University, Lahore, Pakistan
2 shared publicationsVaniza Farrukh
Department of Medicine, Fatima Jinnah Medical University, Lahore, Pakistan
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health
- Vol. 4 (2) , 137-138
Limitations of observational evidence in linking smoking exposure to cardiovascular biomarkers
Was not provided for this article.
- 1 May 2026
- Published by Wolters Kluwer Health
- Vol. 4 (2) , 137-138
Open AccessLimitations of observational evidence in linking smoking exposure to cardiovascular biomarkers
Was not provided for this article.
- 23 March 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1-3
Limitations in PAR1-Targeted Screening of Antithrombotic Phytochemicals
- 23 March 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1-3
Limitations in PAR1-Targeted Screening of Antithrombotic Phytochemicals
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Current Cardiology
- Vol. 4 (1) , 54-55
Critical appraisal of pulse pressure associations in cardiovascular–kidney–metabolic disease
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Current Cardiology
- Vol. 4 (1) , 54-55
Open AccessCritical appraisal of pulse pressure associations in cardiovascular–kidney–metabolic disease
- 31 October 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (4) , e106-e107
Beyond binary rescue: Critical gaps in current failure-to-rescue metrics
- 31 October 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (4) , e106-e107
Beyond binary rescue: Critical gaps in current failure-to-rescue metrics
- 30 October 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (5) , e122-e123
Oral anticoagulation after valve surgery: Gaps in evidence from the Left Atrial Appendage Occlusion Study III substudy
- 30 October 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (5) , e122-e123
Oral anticoagulation after valve surgery: Gaps in evidence from the Left Atrial Appendage Occlusion Study III substudy
- 28 October 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (6) , 2327-2328
Revisiting the association between dysphagia and chronic kidney disease
- 28 October 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (6) , 2327-2328
Revisiting the association between dysphagia and chronic kidney disease
- 10 September 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (11) , 2172-2173
Melatonin for prevention of delirium in patients receiving mechanical ventilation in the intensive care unit
- 10 September 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (11) , 2172-2173
Melatonin for prevention of delirium in patients receiving mechanical ventilation in the intensive care unit
- Open Access
- 3 September 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (2) , 739
Optimizing Risk Stratification in HTG-AP and DKA: The Case for Broader Biomarker Inclusion
- 3 September 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (2) , 739
Open AccessOptimizing Risk Stratification in HTG-AP and DKA: The Case for Broader Biomarker Inclusion
- Open Access
- 13 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6870-6871
Integrative AI-metabolomics: a new frontier in diagnosing pulmonary tumor thrombotic microangiopathy
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, rapidly progressive malignancy-related pulmonary vascular condition that remains difficult to diagnose before death due to its nonspecific clinical and imaging features. Recent advances in metabolomics, particularly when powered by artificial intelligence (AI), offer promising opportunities for early detection by identifying distinct metabolic signatures. While AI-driven metabolomics has shown success in various cancers, its application to PTTM is challenged by the rarity of the disease, limited datasets, and privacy concerns. Innovations such as multicenter collaborations and blockchain-based data sharing may help overcome these barriers. Integrating AI and metabolomics has the potential to revolutionize not only the diagnosis of PTTM but also other rare diseases with elusive early biomarkers.
- 13 August 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (10) , 6870-6871
Open AccessIntegrative AI-metabolomics: a new frontier in diagnosing pulmonary tumor thrombotic microangiopathy
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, rapidly progressive malignancy-related pulmonary vascular condition that remains difficult to diagnose before death due to its nonspecific clinical and imaging features. Recent advances in metabolomics, particularly when powered by artificial intelligence (AI), offer promising opportunities for early detection by identifying distinct metabolic signatures. While AI-driven metabolomics has shown success in various cancers, its application to PTTM is challenged by the rarity of the disease, limited datasets, and privacy concerns. Innovations such as multicenter collaborations and blockchain-based data sharing may help overcome these barriers. Integrating AI and metabolomics has the potential to revolutionize not only the diagnosis of PTTM but also other rare diseases with elusive early biomarkers.